NCT02055274已完成1 期
A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 5
- 主要终点
- Cmax for the Pharmacokinetics (PK) of LY03003
研究概览
简要总结
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary efficacy of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has Idiopathic Parkinson's Disease defined by the cardinal sign, Bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism
- •Subject is Hoehn & Yahr stage ≤3
- •Subject is male or female aged ≥18 years at Screening
- •Subject has a Mini Mental State Examination (MMSE) score of ≥25
- •Subject has a Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) of ≥10 but ≤30 at Screening
排除标准
- •Subject has atypical Parkinson's syndrome(s) due to drugs (e.g., Metoclopramide, Flunarizine), metabolic neurogenetic disorders (e.g., Wilson's Disease), Encephalitis, Cerebrovascular Disease, or Degenerative Disease (e.g., progressive Supranuclear Palsy)
- •Subject has a history of Pallidotomy, Thalamotomy, deep brain stimulation, or fetal tissue transplant
- •Subject has dementia, active psychosis or hallucinations, or clinically significant depression
- •Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (CSSRS) at Screening
- •Subject has a history of symptomatic orthostatic hypotension with a decrease of ≥20 mmHg in systolic blood pressure (SBP) or ≥10 mmHg in diastolic blood pressure when changing from supine to standing position after having been at supine position for at least 5 minutes within 28 days prior to the Screening Visit, or SBP less than 105 mmHg at study entry, or reports clinical signs of clinically significant orthostatic hypotension within 28 days prior to the Screening Visit.
- •Subject is receiving therapy with a dopamine agonist (DA) either concurrently or has done so within 28 days prior to the Screening
- •Subject is receiving therapy with 1 of the following drugs either concurrently or within 28 days prior to screening: MAO-B inhibitors, DA releasing agents, DA modulating agent, DA antagonists, neuroleptics, or other medications that may interact with DA function.
- •Subject is currently receiving central nervous system active therapy (e.g., sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable for at least 28 days prior to Screening Visit and is likely to remain stable for the duration of the study. Patients should not take those medications within 8 hours prior to clinical visits
- •Subject has a current diagnosis of epilepsy, has a history of seizures as an adult, has a history of stroke, or has had a transient ischemic attack within 1 year prior to Screening
- •Subject has a history of known intolerance/hypersensitivity to non-dopaminergic antiemetics, such as domperidone, ondansetron, tropisetron, and glycopyrrolate
- •Subject has any other clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality including abnormal plasma magnesium level, which would in the judgment of the investigator, interfere with the subject's ability to participate in the study
- •Subject has a history of significant skin hypersensitivity to adhesive or other transdermal preparations or recent unresolved contact Dermatitis (this item is specific for patients to be enrolled to part 2 of this study)
- •Subjects with C-reactive protein levels of 2x of upper limit of normal range
- •Female subjects who are pregnant or are breastfeeding or are of childbearing potential without adequate contraception.
- •Patients with a positive finding in drug screening test or alcohol test
研究组 & 干预措施
LY03003
Experimental
4 Stable doses of LY03003 14, 28, 42 and 56 mg
干预措施: LY03003 (Drug)
Neupro
Active Comparator
Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
干预措施: Neupro (Drug)
Neupro PK
Active Comparator
Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
干预措施: Neupro (Drug)
结局指标
主要结局
Cmax for the Pharmacokinetics (PK) of LY03003
时间窗: 5 Weeks
次要结局
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(5 Weeks)
- Preliminary efficacy evaluation will be carried out based on Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III)(5 Weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDParkinson DiseaseNCT04630860Luye Pharma Group Ltd.30
已完成
1 期
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective DisorderSchizophreniaSchizoaffective DisorderNCT02055287Luye Pharma Group Ltd.36
已完成
1 期
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005Major Depressive Disorder, Recurrent, UnspecifiedNCT02271412Luye Pharma Group Ltd.58
已完成
1 期
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003Parkinson DiseaseNCT04627155Luye Pharma Group Ltd.20
已完成
1 期
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.HealthyNCT04081844Hanmi Pharmaceutical Company Limited31